Communiqués Spermosens AB

Actions

SPERM

SE0015346424

Cours en clôture NORDIC GROWTH MARKET 13/08/2026			Varia. 5j.	Varia. 1 janv.
0,009000 ^SEK	+4,65%		0,00%	+55,17%

06/08	Spermosens réalise une augmentation de capital réservée de 4,65 millions de couronnes	FW
21/07	Le conseil d'administration de Spermosens mobilise 4,9 millions de couronnes via sa facilité de capital	MT

Communiqués

06/08	Spermosens: Notice of Extraordinary General Meeting in Spermosens AB (publ)	PU
06/08	Notice of Extraordinary General Meeting in Spermosens AB (publ)	AQ
06/08	Spermosens: Spermosens raises approx. SEK 4.85m in directed issue and calls EGM	PU
06/08	Spermosens raises approx. SEK 4.85m in directed issue and calls EGM	AQ
21/07	Spermosens calls SEK 4.85 million under previously announced Capital Facility	AQ
01/07	Spermosens provides an update on the Generation 3 clinical study	AQ
18/06	Bulletin from Annual General Meeting in Spermosens AB (publ)	AQ
28/05	Spermosens publishes annual report for the financial year 2025	AQ
18/05	NOTICE OF ANNUAL GENERAL MEETING 2026 IN SPERMOSENS AB (publ)	AQ
11/05	Spermosens AB (publ) to Host Live Q&A Webcast on 19 May 2026	AQ
07/05	Spermosens secures SEK 4.85 million capital facility to support development and commercialization	AQ
07/05	Spermosens AB (publ) INTERIM REPORT JANUARY - MARCH 2026	AQ
29/04	Spermosens reports JUNO-Checked Generation 3 clinical validation study on track	AQ
08/04	Spermosens: Spermosens completes development of JUNO-Checked Generation 3 and initiates clinical validation study	PU
08/04	Spermosens completes development of JUNO-Checked Generation 3 and initiates clinical validation study	AQ
25/03	Spermosens AB (publ) Issues Final Reminder for Tomorrow's Live Q&A Webcast	AQ
16/03	Spermosens AB (publ) to Host Live Q&A Webcast Following Recent Progress	AQ
11/02	Spermosens: Spermosens AB (publ)YEAR-END REPORT JANUARY – DECEMBER 2025	PU
11/02	Spermosens AB (publ)YEAR-END REPORT JANUARY - DECEMBER 2025	AQ
26/01	Spermosens and RSI sign Memorandum of Understanding to advance male fertility diagnostics in the US	AQ
16/01	Spermosens and Sapyen sign Memorandum of Understanding to advance male fertility diagnostics	AQ
09/12	Spermosens shares progress and plans for partner-driven commercialization	AQ
08/12	Spermosens announces outcome of exercise of warrants series TO 4	AQ
24/11	Spermosens announces last day of trading for warrants of series TO 4	AQ
18/11	Spermosens receives patent approval in China	AQ